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Summary
IGF-IR-mediated signaling promotes survival, anchorage-independent growth, and oncogenic transformation, as well as
tumor growth and metastasis formation in vivo. NVP-AEW541 is a pyrrolo[2,3-d]pyrimidine derivative small molecular
weight kinase inhibitor of the IGF-IR, capable of distinguishing between the IGF-IR (IC50  0.086 M) and the closely related
InsR (IC50  2.3 M) in cells. As expected for a specific IGF-IR kinase inhibitor, NVP-AEW541 abrogates IGF-I-mediated
survival and colony formation in soft agar at concentrations that are consistent with inhibition of IGF-IR autophosphorylation.
In vivo, this orally bioavailable compound inhibits IGF-IR signaling in tumor xenografts and significantly reduces the growth
of IGF-IR-driven fibrosarcomas. Thus, NVP-AEW541 represents a class of selective, small molecule IGF-IR kinase inhibitors
with proven in vivo antitumor activity and potential therapeutic application.
Introduction tega and Osborne, 1989; De Leon et al., 1992), or dominant
negative mutants (Prager et al., 1994; D’Ambrosio et al., 1996;
The insulin-like growth factor I receptor (IGF-IR) is a tetrameric Reiss et al., 1998), was found to interfere with cell growth and
transmembrane receptor tyrosine kinase composed of two  proliferation. In particular, IGF-I signaling was demonstrated to
and two  subunits linked by disulfide bonds. The extracellular  play a vital role in cellular transformation. Overexpression of the
subunit is responsible for ligand binding, whereas the  subunit IGF-IR is sufficient to transform immortalized mouse fibroblasts,
consists of a transmembrane domain and a cytoplasmic tyrosine as assayed by survival and growth in soft agar and the formation
kinase domain (for review, see Ullrich and Schlessiger, 1990; of tumors in nude mice (Kaleko et al., 1990), whereas fibroblasts
Van der Geer et al., 1994). The receptor is primarily activated genetically deficient for the IGF-IR gene are resistant to transfor-
by its cognate ligands, insulin-like growth factor I (IGF-I) and II mation by SV40 T antigen, c-Src, Ras, PDGFR, or EGFR (Sell
(IGF-II; 2- to 15-fold lower affinity), and, albeit at a much lower et al., 1993, 1994; Coppola et al., 1994; De Angelis et al., 1995;
affinity (500- to 1000-fold less), by insulin. Ligand binding acti- Valentinis et al., 1997).
vates the intrinsic tyrosine kinase activity, resulting in trans- Several experimental approaches have demonstrated the
subunit autophosphorylation and stimulation of signaling cas- therapeutic potential of interfering with IGF-IR-mediated signal-
cades that include the IRS-1/PI-3K/PKB/S6K and Grb2/Sos/ ing in vivo. Inhibition of primary tumor growth was achieved
Ras/MAPK pathways. Activation of the IGF-IR has been re- with IGF-IR blocking antibodies (Scotlandi et al., 1998), upon
ported to result in proliferation, survival, transformation, metas- overexpression of a dominant negative mutant (Reiss et al.,
tasis, and angiogenesis (for review, see Baserga, 2000; Wang 1998; Prager et al., 1994; D’Ambrosio et al., 1996; Kalebic et
and Sun, 2002). al., 1998; Li et al., 2000; Scotlandi et al., 2002a), as well as by
Extensive studies have demonstrated that IGF-I acts as a means of antisense cDNA or oligonucleotides to downregulate
mitogen both in vitro and in vivo. In fact, IGF-I, together with IGF-IR expression (Resnicoff et al., 1994, 1995; Shapiro et al.,
PDGF, was originally shown to be essential for the proliferation 1994; Nakamura et al., 2000). Additional antisense studies sug-
gested an important role for IGF-IR in invasion and metastasisof fibroblasts in vitro (Stiles et al., 1979). Downregulation of IGF-IR
function, by either gene disruption (Sell et al., 1994), antisense formation (Long et al., 1995; Burfeind et al., 1996; Dunn et al.,
1998; Chernicky et al., 2000; Samani et al., 2001; Scotlandioligonucleotides (White et al., 2000), neutralizing antibodies (Ar-
S I G N I F I C A N C E
Insulin-like growth factors and their receptor tyrosine kinase, IGF-IR, have been implicated in the development and progression of
cancer, by contributing proliferative, antiapoptotic, transforming, and proangiogenic signaling. The clinical development of the
orally bioavailable, selective, small molecule kinase inhibitor of the IGF-IR, NVP-AEW541, will provide the unique opportunity to
perform clinical proof-of-concept studies to test this novel therapeutic strategy in oncology.
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et al., 2002b). This hypothesis was further reinforced by the Table 1. In vitro inhibitory activity and selectivity of NVP-AEW541
enhanced transition to invasive carcinoma and formation of Enzyme IC50 [M]  SEM n Kinase type
metastases observed upon targeted overexpression of the
IGF-IR 0.15  0.036 6 TyrIGF-IR in the RipTag model of pancreatic carcinogenesis (Lopez
Ins-R 0.14  0.039 5 Tyr
and Hanahan, 2002). HER-1 5.8  1.4 4 Tyr
Epidemiological evidence for a role of IGF-IR signaling in HER-2 4.1  1.4 5 Tyr
HER-4 1.4  0.41 2 Tyrcancer has emerged from various studies demonstrating in-
KDR 2.3  0.24 5 Tyrcreased expression levels of multiple components of the IGF
Tek 0.53  0.22 3 Tyrsignaling system in diverse tumor types (for review, see Yu and PDGFR 2.0  0.61 3 Tyr
Rohan, 2000; Khandwala et al., 2000; Grimberg and Cohen, c-Met 3.8  1.0 4 Tyr
c-Abl 10 5 Tyr2000; Fu¨rstenberger and Senn, 2002).
c-Src 2.4  0.38 3 TyrBased on the evidence described above, a drug discovery
c-Kit 3.3  1.4 3 Tyrprogram to identify and develop a potent and selective small
Flt-4 2.4  0.46 3 Tyr
molecular mass inhibitor of the IGF-IR signaling pathway as an Flt-1 0.60  0.13 3 Tyr
anticancer agent was initiated. A major hurdle to this approach Flt-3 0.42  0.11 6 Tyr
FGFR-1 4.1  1.1 4 Tyris the close homology of the IGF-IR and the InsR kinase do-
PKB 10 4 Ser/Thrmains. The ATP binding site of these two receptors displays
Cdk1/Cyc.B 10 3 Ser/Thr100% sequence identity, whereas the entire kinase domains PDK1 4.8  2.1 4 Ser/Thr
share 84% sequence identity, both with each other and across c-Raf-1 10 3 Ser/Thr
PKA 10 3 Ser/Thrspecies.
Hereafter, we describe the in vitro and in vivo characteriza- In vitro kinase assays were performed with the indicated purified kinases/
tion of a potent IGF-IR kinase inhibitor capable of selectively recombinant kinase domains in the absence or presence of increasing
concentrations of NVP-AEW541, as described in the Experimental Proce-inhibiting IGF-IR kinase activity, as opposed to InsR kinase
dures. IC50s are expressed as means  SEM. The number of independentactivity, at the cellular level, and significantly reducing the
IC50 determinations is indicated with n. Tyr: tyrosine-specific protein kinase.growth of IGF-IR-driven fibrosarcomas. Ser/Thr: serine/threonine-specific protein kinase.
Results
Small molecules belonging to the pyrrolo[2,3-d]pyrimidine class
the recombinant kinase domains used in the in vitro kinase
were identified in a high-throughput screening of our in-house
assay. Thus, at the cellular level, NVP-AEW541 is highly selec-
compound archive as inhibitors of the IGF-IR in vitro kinase
tive against the IGF-IR, as compared to both the InsR and other
activity. This compound class was subjected to a medicinal
tyrosine kinases.
chemistry program aimed at optimizing the potency and selec-
Given the survival function that has been ascribed to IGF-IR-
tivity toward the IGF-IR kinase, as well as their drug-like proper-
mediated signaling and the requirement of IGF-IR mediated
ties. NVP-AEW541 is a representative example of such an opti-
signaling for cellular transformation, the ability of the compound
mization process, whose potency and selectivity was first
to inhibit IGF-I-mediated survival of MCF-7 cells in the absence
assessed in a series of in vitro kinase assays using different
of serum and to prevent their ability to grow in an anchorage-
recombinant kinase domains or purified kinases and synthetic
independent manner was analyzed. NVP-AEW541 was shown
peptide substrates (Table 1). The compound was found to inhibit
to inhibit IGF-I-mediated survival of MCF-7 cells (Table 3), as
the in vitro kinase activity of the recombinant IGF-IR kinase
well as their ability to grow in soft agar (Table 3), at concentra-
domain with an IC50 value of 0.15 M and to be equipotent tions consistent with its capacity to inhibit receptor autophos-
against the recombinant InsR kinase domain. NVP-AEW541 dis-
phorylation (data not shown).
played at least 10-fold selectivity toward the IGF-IR, as com-
As an effective therapeutic agent, NVP-AEW541 must also
pared to most of the other kinases tested. The only exceptions
be able to inhibit IGF-I-stimulated signaling (Figure 1) and prolif-
were represented by the Flt-1, Flt-3, and Tek kinases, where the
eration in the presence of serum (Table 3). The cell line selected
compound inhibited the respective recombinant kinase domains
for these tests, NWT-21, is a NIH3T3 derivative that stably ex-
with IC50 values 3- to 4-fold higher than those measured for the
IGF-IR.
In order to assess the ability of NVP-AEW541 to inhibit its
target in cells, and to test the selectivity of the compound against Table 2. Cellular inhibitory activity and selectivity of NVP-AEW541
a panel of native tyrosine kinases (IGF-IR, InsR, HER-1, PDGFR,
Enzyme IC50 (M)  SEM nc-Kit, Bcr-Abl), their autophosphorylation was measured in the
IGF-IR 0.086  0.028 5presence or absence of the compound (Table 2). NVP-AEW541
InsR 2.3  0.163 2was confirmed active toward the IGF-IR kinase (IC50  0.086 HER1 10 1
M) and shown to be selective at the cellular level. Indeed, PDGFR 10 1
NVP-AEW541 was found to be 27-fold more potent toward the c-Kit 5 2
Bcr-Abl p210 10 1native IGF-IR, as compared to the structurally related native
InsR. The selectivity observed at the cellular level indicates that, The autophosphorylation of the indicated kinases was determined at the
cellular level in the absence or presence of increasing concentrations ofdespite the 84% identity of the IGF-IR and InsR kinase domains,
NVP-AEW541. IC50s are expressed as means  SEM and the number ofthere are conformational differences between the native forms
independent determinations is indicated with n.of these receptor tyrosine kinases that are not recapitulated by
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Table 3. Inhibition of IGF-I-mediated survival, anchorage-independent
growth, and cellular proliferation by NVP-AEW541
Assay Cell line IC50 (M)  SEM n
IGF-I-mediated survival MCF-7 0.162  0.016 8
Soft agar MCF-7 0.105  0.018 2
Proliferation NWT-21 1.64  0.67 6
The ability of NVP-AEW541 to inhibit IGF-I-mediated survival was assessed in
MCF-7 cells in the absence of serum. Inhibition of anchorage-independent
growth by NVP-AEW541 was assessed in a soft agar assay using MCF-7
cells. The proliferative capacity of NWT-21 cells (NIH3T3 stably expressing
the human IGF-IR) growing in serum-containing media was determined in
the absence and presence of increasing concentrations of the compound.
The IC50 values are expressed as mean  SEM and the number of indepen-
dent determinations is indicated with n.
presses the human IGF-IR. IGF-IR overexpression in murine
fibroblasts is reported to result in transformation, as assayed
by focus formation and tumor growth in nude mice, indicating
that the NWT-21 cells would also represent a suitable IGF-
IR-driven model for further in vivo efficacy studies. IGF-IR-medi-
Figure 2. Inhibition of IGF-IR signaling by NVP-AEW541 in a mouse pharmaco-
ated signaling was monitored both at the level of receptor dynamic model
autophosphorylation and phosphorylation of PKB, which is a Inhibition of IGF-IR-mediated signaling by NVP-AEW541 in murine lung was
downstream signaling event. As shown in Figure 1 and Table determined ex vivo as described in the Experimental Procedures. NVP-
AEW541 was administered p.o. at 50 mg/kg; one hour later, IGF-I at 0.1 mg/3, NVP-AEW541 was capable of effectively inhibiting IGF-IR-
kg was injected i.v., and the tissue was collected 5 min thereafter. IGF-IR,mediated signaling, as well as cellular proliferation, in the pres-
PKB, and MAPK phosphorylation, as well as their total levels to ensure equalence of serum. In addition to phospho-IGF-IR and phospho- loading, were determined ex vivo by immunoprecipitation-Western blot
PKB inhibition, similar dose-dependent reduction in the level of (phospho-IGF-IR) or by Western blot.
phospho-MAPK and phospho-GSK-3 were observed in inde-
pendent experiments, where NWT-21 cells were exposed in
vitro to NVP-AEW541 (data not shown).
gated upon oral administration of NVP-AEW541. Having demon-To assess and compare the activity of IGF-IR inhibitors in
strated the ability of the compound to abrogate IGF-I signalingvivo, a pharmacodynamic model was established. Murine lung
in vivo, its effect on subcutaneously implanted NWT-21 tumorswas selected as a suitable tissue based on the observation that
was assessed. In line with the observations obtained in lungit contains detectable levels of the receptor and that stimulation
tissue, oral administration of NVP-AEW541 resulted in abroga-with IGF-I leads to receptor autophosphorylation and activation
tion of basal and IGF-I-induced receptor, and PKB and MAPKof downstream signaling intermediates, including PKB and
phosphorylation in the NWT-21 tumor xenograft (Figure 3).MAPK. As shown in Figure 2, ligand-mediated IGF-IR autophos-
Finally, the in vivo antitumor activity of NVP-AEW541 wasphorylation and phosphorylation of PKB and MAPK were abro-
assessed in the NWT-21 fibrosarcoma tumor model (Figure 4).
Animals with established NWT-21 subcutaneous tumors were
treated orally (bid, 7/week) with 20 mg/kg, 30 mg/kg, or 50
mg/kg of NVP-AEW541. A consistent and dose-dependent inhi-
bition of tumor growth was observed in compound treated ani-
mals with T/C values of 32%, 28% and 14%, respectively. All
treatment groups had significantly smaller tumor volumes, as
compared to the tumor volumes in the control vehicle group
(Dunnett’s test, p  0.05). NVP-AEW541 was well tolerated at
the doses applied, and the recorded variations in body weight
were not statistically significant. Thus, NVP-AEW541 fulfills the
requirements, in terms of potency, specificity, oral bioavailability
and in vivo activity, to represent an effective IGF-IR targeting
anticancer agent.
Figure 1. Inhibition of IGF-IR signaling by NVP-AEW541 in NWT-21 cells Discussion
Inhibition of IGF-IR-mediated signaling by NVP-AEW541 was determined
in NWT-21 cells, a derivative of NIH3T3 mouse fibroblasts obtained upon NVP-AEW541 is an optimized IGF-IR kinase inhibitor that selec-
overexpression of the human IGF-IR. Cells were grown as a monolayer, tively distinguishes between the native IGF-IR and the closely
exposed to NVP-AEW541, and stimulated with IGF-I. IGF-IR and PKB phos-
related InsR. The selectivity toward the IGF-IR is observed atphorylation, as well as their total protein levels, were determined by Western
blot as described in the Experimental Procedures. the cellular level (27-fold), but not in the in vitro kinase assays,
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ing with the notion that IGF-IR-mediated signaling is key for the
growth of tumor cells under anchorage-independent conditions,
but less so for their growth as adherent monolayer, higher con-
centrations of compound were generally required to inhibit pro-
liferation of tumor cells in monolayer cultures than in the soft
agar. Furthermore, cell-cell contact has been observed to nega-
tively influence the sensitivity of cells to IGF-IR inhibitors (data
not shown), probably because other, cell-contact-driven, sur-
vival mechanisms come into play. Thus, inhibition of IGF-IR
signaling is likely to be more efficacious in inhibiting the onset
of metastasis than the growth of an established primary tumor,
unless the latter is exquisitely IGF-dependent. This view is sup-
ported by studies in which impairment of IGF-IR function, either
through the use of antisense molecules or dominant negative
mutants (Long et al., 1995; Dunn et al., 1998), led to a reduction
in the number of metastasis, but not the primary tumor.
Figure 3. Inhibition of IGF-IR signaling by NVP-AEW541 in NWT-21 tumor xeno-
To first assess the in vivo antitumor efficacy of NVP-grafts
AEW541, we utilized a mechanistic IGF-IR-driven tumor model,Inhibition of IGF-IR-mediated signaling by NVP-AEW541 in subcutaneous
obtained by ectopic expression of the human IGF-IR in NIH3T3NWT-21 tumors was determined ex vivo as described in the Experimental
Procedures. NVP-AEW541 was administered p.o. at 50 mg/kg; one hour mouse fibroblasts. This cellular system was shown to respond
later, tumor tissue was collected with or without prior stimulation with IGF-I to NVP-AEW541 in vitro in terms of both reduced proliferative
(0.1 mg/kg) by i.v. injection. IGF-IR, PKB, and MAPK phosphorylation, as well capacity and IGF-IR-mediated signaling. Prior to performing the
as their total levels to ensure equal loading, were determined ex vivo by
efficacy studies, NVP-AEW541 was demonstrated to stronglyWestern blot.
inhibit IGF-IR-mediated signaling in both a pharmacodynamic
model and in subcutaneously implanted NWT-21 tumors. Con-
sistently with IGF-IR signaling inhibition, NVP-AEW541 was
found to significantly impair the growth of subcutaneously im-where recombinant protein fragments corresponding to the re-
planted NWT-21 tumors, thereby demonstrating the efficacy ofspective kinase domains are used. It is conceivable that struc-
this inhibitor toward IGF-IR driven tumors in vivo.tural features peculiar to each of these two receptors, but absent
Despite the cellular selectivity achieved toward the IGF-IR,in the recombinant kinases, affect and differentiate the confor-
as compared to the InsR, there remains a potential risk of suchmation of the respective kinase domains in the context of the
a compound interfering with glucose/insulin metabolism. In fact,native receptors. Similar observations were obtained in the case
the two receptors can form heterodimers, a situation where aof Flt-3, where the selectivity of NVP-AEW541 toward the IGF-IR
selective IGF-IR inhibitor would prevent crossphosphorylationimproved from 2.8-fold in vitro to 21-fold at the cellular level
and activation of the associated InsR heterodimeric partner.(data not shown).
Alternatively, the compound could in principle accumulate atThe compound was found to fulfill the key characteristics
concentrations high enough to also inhibit the InsR. To assessexpected from an IGF-IR inhibitor. It effectively inhibits the sur-
this potential risk, plasma glucose and plasma insulin were mon-vival function ascribed to IGF signaling and prevents the ability
itored in mice treated with efficacious doses (50 mg/kg, bid,of transformed cells to grow in an anchorage-independent man-
p.o.) of NVP-AEW541. No significant differences were observedner, both events occurring at concentrations that are consistent
with its capacity to inhibit IGF-IR autophosphorylation. In keep- when the plasma glucose and insulin levels of vehicle and com-
Figure 4. Inhibition of tumor growth by oral ad-
ministration of NVP-AEW541 in a fibrosarcoma
model
Tumors were established in female nude mice
(Hsd:Athymic Nude-nu) by subcutaneous im-
plantation of NWT-21 tumor fragments (3  3 
3 mm) obtained from donor mice. Seven days
after implantation (day 0), treatment with NVP-
AEW541 was started at doses of 20 mg/kg, 30
mg/kg, and 50 mg/kg p.o. bid, 7/week. Vehicle
controls received 25 mM L(	)-tartaric acid p.o.
bid, 7/week. Tumor volumes were determined
according to the formula L  W  H  
 / 6 and
are shown in mm3 as mean  SEM. Body weights
are shown in g as mean  SEM. The experiment
was terminated 11 days after start of treatment.
*p  0.05 (Dunnett’s) versus control vehicle.
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6H2O, 200 g/mL Protamine sulfate, 1 % DMSO, 10 M ATP, and 0.1 Cipound treated animals were compared after 10 days of treat-
[33P]ATP (37–110 TBq/mmol).ment (see Supplemental Table S1 at http://www.cancercell.org/
Cdk1/cycBcgi/content/full/5/3/231/DC1), indicating that at least under
The enzyme was isolated from starfish oocytes by Dr. L. Meijer (CNRS
these conditions, antitumor activity could be achieved without Roscoff, France). Starfish oocytes were induced to enter M phase of the
affecting the concentration of glucose and insulin in plasma. cell cycle with 10 M 1-methyladenine, frozen in liquid nitrogen, and stored
Thus, NVP-AEW541 specifically targets the IGF-IR and rep- at80C. The oocytes were then homogenized following thawing and centri-
fuged as described (Arion et al., 1988; Rialet and Meijer, 1991). The superna-resents a novel, potential therapeutic strategy for the treatment
tant from oocytes was equilibrated for 30 min at 4C under constant rotationof tumor types for which IGF-IR-mediated signaling is a required
with the p9CKShs-sepharose beads. After extensive washing, elution of Cdk1/driving/survival function. One such tumor type is likely to be
cycB kinase from the p9CKShs-sepharose beads was performed with recombi-multiple myeloma, for which dependency on IGF-signaling and
nant human p9CKShs (3 mg/ml) as described (Azzi et al., 1992). The activity
sensitivity to a closely related IGF-IR kinase inhibitor have been of Cdk1/cycB was measured as described (Azzi et al., 1992; Meijer et al.,
demonstrated in vitro and in vivo in the accompanying manu- 1989, 1991) with slight modifications. The enzyme assay was carried out
script (Mitsiades et al., 2004, this issue of Cancer Cell). for 30 min at RT in a final volume of 30 l containing 0.1–0.3 U of Cdk1/
cycB, 0.1 mg/ml histone H1 (Sigma; St. Louis, Mo., USA) as a substrate,
Experimental procedures 60 mM -glycerophosphate, 30 mM nitrophenylphosphate, 25 mM MOPS,
5 mM EGTA (pH 8.0), 15 mM MgCl2, 1 mM DTT, 0.1 mM Na3VO4, 1 % DMSO,
In vitro kinase assays 7.5 M ATP and 0.1 Ci [33P]ATP (37–110 TBq/mmol).
The protein kinases were cloned, expressed, purified, and assayed according PKA
to the following procedure unless explicitly stated otherwise. pFbacG01, The catalytic domain of PKA was assayed according to the manufacturer’s
pFbacGST2T, and pFbacGSTx3 Bac-to-Bac donor vectors were generated procedure (Sigma; St. Louis, Mo., USA). In brief, liophilized PKA from rabbit
from the pFastBac1 vector (GIBCO-BRL; Cheshire, UK) by insertion of the muscle was reconstituted in nanopure water and frozen 20C as stock
GST coding sequence from pAcG1, pAcG2T, and pAcG3X, respectively aliquots (5000 U/ml). The heptapeptide Leu-Arg-Arg-Ala-Ser-Leu-Gly,
(PharMingen; San Diego CA, USA). The kinase coding sequences were then known as Kemptide (Bachem; Bubendorf, Switzerland), was used as peptide
fused to GST and sequence identity was confirmed. substrate. The enzyme assay was carried out for 20 min at RT in a final
Viruses for each of the kinases were generated in Sf9 (ATCC# CRL- volume of 30 l containing 1 U of PKA, 100 mM MES-NaOH (pH 7.0), 15
1711) or Sf21 (ATCC# VR-2209) cells (American Type Culture Collection; mM Mg(OAc)2  (4H2O), 225 mM NaCl, 50 M ATP (0.1 Ci [33P]ATP (37-
Manassas, VA, USA) according to the protocol supplied by GIBCO-BRL 110TBq/mmol), 0.3 mg/ml Kemptide, 0.75 mM EDTA (pH 7.0), 3.0 mg/ml
(Cheshire, UK), unless stated otherwise. bovine serum albumin, 1 % DMSO and 10% glycerol.
For large-scale protein expression, 100 cm2 round tissue culture plates c-raf-1
were seeded with 5  107 cells/plate and infected with 1 ml of virus-con- Production of recombinant c-Raf-1 was performed by triple infection of
taining media (5 MOIs). After 3 days, the cells were scraped off the plate Sf21 cells with GST-c-Raf-1 baculovirus together with v-Src and v-Ras
and centrifuged at 500 rpm for 5 min. Cell pellets from 10–20 100 cm2 plates baculoviruses that are required for active c-Raf-1 kinase production (Williams
were resuspended in 50 ml of ice-cold lysis buffer (25 mM Tris·HCl [pH 7.5], et al., 1992). Active Ras (v-Ras) is required to recruit c-Raf-1 to the cell
2 mM EDTA, 1% NP-40, 1 mM DTT, 1 mM PMSF). The cells were stirred membrane, and v-Src is required to phosphorylate c-Raf-1 to fully activate
on ice for 15 min and then centrifuged at 5000 rpm for 20 min. The clear it (Williams et al., 1992). IB, expressed in bacteria as a His-tagged protein,
lysate was loaded onto a 2 ml glutathione-sepharose column (Pharmacia; was used as substrate for the c-Raf-1 kinase. Bacteria were lysed by sonica-
Du¨bendorf, Switzerland) and washed three times with 10 ml of 25 mM tion (microtip limit setting for 3 times at 1 min each) in sonication buffer (50
Tris•HCl (pH 7.5), 2 mM EDTA, 1 mM DTT, and 200 mM NaCl. The GST- mM Tris·HCl [pH 8.0], 1 mM DTT, 1 mM EDTA) and centrifuged at 10,000 
tagged proteins were then eluted by 10 applications (1 ml each) of 25 mM g for 15 min. The supernatant was mixed with ammonium sulfate to give a
Tris·HCl (pH 7.5), 10 mM reduced glutathione, 100 mM NaCl, 1 mM DTT, final concentration of 30%. This mixture was rocked for 15 min at 4C then
and 10% Glycerol, and stored at 70C.
spun at 10,000 g for 15 min. The pellet was resuspended in binding buffer
The activities of protein kinases were assayed in the presence or ab-
containing 10 mM BSA. This solution was applied to Ni-agarose and washed
sence of inhibitors by measuring the incorporation of 33P from [33P]ATP
according to the manufacturer. IB was eluted from the column using elution
(1000 Ci/mmol; Amersham; Little Chalfont, UK) into appropriate substrates.
buffer (8 mM Tris·HCl [pH 7.9], 0.2 M NaCl, 0.4 M imidazole). Fractions
NVP-AEW541 was dissolved in DMSO (10 mM) and stored at 20C. Dilu-
containing protein were dialyzed in 50 mM Tris·HCl (pH 8), 1 mM DTT. The
tions were freshly made in DMSO/water 1:1. The final concentration of DMSO
enzyme assay was carried out for 45 min at RT in a final volume of 30 lin the enzyme assays was 0.5 %. The protein kinase assays were carried
containing 750–1000 ng GST-c-Raf-1 kinase, 20 mM Tris•HCl (pH 7.5), 3.0out in 96-well plates at RT under conditions described in details below and
mM MgCl2, 3.0 mM MnCl2, 10 M Na3VO4, 1 mM DTT, 1 % DMSO, 1.0 Mterminated by the addition of 20 l of 125 mM EDTA. Subsequently, 30 l
ATP (0.1 Ci/assay [-33P]-ATP), and 3.0 g/mL IB.(c-Abl, c-Src, IGF-1R) or 40 l (all other kinases) of the reaction mixture
PKB/Aktwere transferred onto Immobilon-PVDF (Millipore; Bedford, MA, USA) pre-
The  isoform of human PKB/Akt was kindly provided by Dr. T. Robertssoaked for 5 min with methanol, rinsed with water, then soaked for 5 min
(DFCI, Boston, USA). The kinase assays were performed as described (Alessiwith 0.5 % H3PO4 and mounted on vacuum manifold. After spotting all
et al., 1996) with slight modifications. The assay was carried out for 30 minsamples, vacuum was connected and each well rinsed with 200 l 0.5 %
at ambient temperature in a final volume of 30 l containing 51 mM MOPSH3PO4. Membranes were removed and washed 4 on a shaker with 1.0 %
(pH 7.2), 1.05 mM DTT, 5.0 mM MgCl2  (6H2O), 0.01% Triton X-100, 100H3PO4, once with ethanol. After drying, mounting in Packard TopCount 96-
M [33P]ATP (0.1Ci/vial), 0.050 mM Crosstide (GRPRTSSFAEG, manufac-well frame, and adding of 10 l/well of Microscint (PerkinElmer Schweiz;
tured in-house), and 0.1–0.3 U of PKB/Akt.Hu¨hnenberg, Switzerland), membranes were counted. IC50 values were cal-
HER-1, HER-2, HER4culated by linear regression analysis of the percentage inhibition of each
The HER-1 and HER-2 cDNAs were kindly provided by Dr. Nancy Hynescompound in duplicate, at four concentrations (usually 0.01, 0.1, 1, and 10
(FMI, Basel, Switzerland). Recombinant baculovirus was generated that ex-M). One unit of protein kinase activity is defined as 1 nmole of 33P transferred
presses the amino acid region 668–1210 and 676–1255 of the cytoplasmicfrom [33P]ATP to the substrate protein per minute per mg of protein at 37C.
kinase domains of human HER-1 and HER-2, respectively. The coding se-PKC-
quence for HER-4 kinase domain (aa 676–1308) was amplified by PCR fromExpression of recombinant bovine PKC- using the baculovirus system has
a human uterus cDNA library. The kinase assays with purified GST-HER-1been described (Stabel et al., 1991; Geiges et al., 1997). PKC-was partially
(3 ng), GST-HER-2 (10 ng), and GST-HER-4 (4 ng) were carried out for 15purified by DEAE sepharose (Pharmacia; Du¨bendorf, Switzerland). The en-
min at RT in a final volume of 30 l containing 20 mM Tris·HCl (pH 7.5), 10zyme assay was carried out for 20 min at RT in a final volume of 30 l
containing 0.1–0.3 U of PKC-, 20 mM Tris•HCl (pH 7.4), 10 mM Mg(NO3)2  mM MgCl2, 3 mM MnCl2, 0.01 mM Na3VO4, 1 % DMSO, 1 mM DTT, 3 g/mL
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poly(Glu,Tyr) 4:1 (Sigma; St. Louis, Mo., USA), and 2.0 M ATP (-[33P]-ATP Ins-R cDNA (Pronk et al., 1994). The cells were cultured in DMEM medium
containing 10% FCS and 1% penicillin/streptomycine. The human epider-0.1 Ci).
c-Abl moid carcinoma cell line A431 (ATCC CRL1555) was grown in Dulbecco’s
modified Eagle’s medium (DMEM) supplemented with 10% fetal bovineThe His-tagged kinase domain of c-Abl was cloned and expressed in the
baculovirus/Sf9 system as described (Bhat et al., 1997). A protein of 37 kDa serum, in presence of 1% sodium pyruvate and 1% penicillin/streptomycin.
A31 cells (BALB/3T3 clone A31, ATCC CCL-163) were grown in DMEM high-(c-Abl kinase) was purified by a two-step procedure over a cobalt metal
chelate column followed by an anion exchange column (Pharmacia; Du¨ben- glucose with 10% FCS, 1% L-Glutamine, and 1% penicillin/streptomycin.
GIST882 cells, originally derived from a human gastrointestinal stromal tu-dorf, Switzerland) with a yield of 1–2 mg/l of Sf9 cells (McGlynn et al., 1992).
Tyrosine protein kinase assays with purified c-Abl contained in a total volume mor, were obtained from Jonathan A. Fletcher (DFCI, Boston) and cultivated
in RPMI 1640, supplemented with 15% FCS, and 2 mM glutamine. Theseof 30 l: 10 ng c-Abl kinase, 20 mM Tris·HCl (pH 7.5), 10 mM MgCl2, 10
M Na3VO4, 1 mM DTT, 1 % DMSO, 5 M ATP (0.07 Ci/assay [-33P]-ATP) cells express a mutated kit that is constitutively activated. The murine my-
eloid progenitor cell line 32Dcl3 transfected with the p210 Bcr-Abl expressionand 30 g/ml Poly-AEKY (poly-Ala,Glu,Lys,Tyr-6:2:5:1; Sigma; St. Louis,
Mo., USA) and were carried out for 10 min at RT. vector pGDp210Bcr/Abl (32D-bcr/abl) was obtained from J. Griffin (Bazzoni
et al., 1996). The cells express the fusion bcr-abl protein with a constitutivelyc-Src
The baculovirus expressing full-length chicken c-Src was generated as a active abl kinase and proliferate in an IL-3-independent manner. The cells
were grown in RPMI 1640, 10% fetal calf serum, 2 mM glutamine. All cellGST fusion protein. The assay contained in a final volume of 30 l: 5 ng
c-Src kinase, 20 mM Tris·HCl (pH 7.5), 10 mM MgCl2, 0.01 mM Na3VO4, 1% culture reagents were purchased from Invitrogen (Basel, Switzerland).
DMSO, 1 mM DTT, 25 g/ml poly(Glu,Tyr) 4:1 (Sigma; St. Louis, Mo., USA),
20 M ATP (-[33P]-ATP 0.07 Ci), and was carried out for 10 min at RT. Cellular autophosphorylation assays
IGF-IR, Ins-R 96-well capture ELISAs were established to measure inhibition of either
The baculovirus expressing the amino acid region 950–1337 of the mature ligand-induced receptor autophosphorylation (IGF-IR, InsR, EGF-R, PDGFR)
cytoplasmic domain of the human IGF-IR was generated as a GST fusion or the reduction of autophosphorylation of the constitutively active kinases
protein. Similarly, a baculovirus expressing the amino acid region 919–1343 (c-Kit, Bcr-Abl). For all described capture ELISAs, phoshorylated target was
of the cytoplasmic kinase domain of the human insulin receptor, Ins-R, was detected using the AP-labeled anti-phosphotyrosine Ab PY20(AP) as second
generated. Tyrosine protein kinase assays with purified GST-IGF-IR (100 ng) Ab and the chemiluminescent AP-substrate CDPStar RTU with Emerald II.
and GST-Ins-R (50 ng) were performed in a final volume of 30l containing 20 IGF-IR
mM Tris•HCl (pH 7.6), 10 mM MgCl2, 0.01 mM Na3VO4, 1 % DMSO, 1 mM NWT-21 cells were seeded into 96-well tissue culture plates (Costar; Wohlen,
DTT, 3 g/ml 1.0 M (Ins-R), and 30 M (IGF-IR) of poly(Glu,Tyr) 4:1 (Sigma; Switzerland) at 5000 cells/well in complete growth medium and grown to
St. Louis, Mo., USA), and 0.1 Ci ATP (-[33P]-ATP). The assay was carried 70%–80% confluency by incubation at 37C, 5% CO2. After starvation for
out for 20 min at RT. 24 hr in DMEM, 0.5% FCS, the cells were incubated for 90 min in presence
KDR, Flt-1, Flk-1, Tek, c-Met, c-Kit, c-Fms, PDGFR-, FGFR-1 or absence of test compound followed by stimulation with IGF-I (final concen-
Recombinant baculovirus for the KDR (aa 807–1350), Flt-1 (aa 784–1338), tration: 10 ng/ml) for 10 min at 37C. Subsequently, the cells were washed
Flk-1 (aa 792–1367), Tek (aa 773–1124), and PDGFR- (aa 661–1106) kinase twice with ice-cold PBS and lysed at 4C with 50 l/well RIPA-buffer (50
domains fused N-terminally to GST were provided by the lab of Dr. Marme´ mM Tris·HCl [pH 7.2], 120 mM NaCl, 1 mM EDTA, 6 mM EGTA, 1% NP-40,
(Klinik fu¨r Tumour Biologie, Freiburg, Germany). The coding sequences for 20 mM NaF, 1 mM benzamidine, 15 mM sodium pyrophosphate, 1 mM
the cytoplasmic domain of c-Kit (aa 544–976) and c-Fms (aa 538–972) were PMSF, and 0.5 mM Na3VO4).
amplified by PCR from human uterus and from human bone marrow cDNA MAB 24-60 was used as capture antibody for the IGF-IR. The hybridoma
libraries (Clontech; Palo Alto CA, USA), respectively. The assays (30 l) line producing this anti-IGF-IR monoclonal antibody was originated by K.
contained 200–1800 ng of enzyme protein (depending on the specific activ- Siddle (University of Cambridge, Cambridge, UK) and obtained from L. Schu-
ity), 20 mM Tris•HCl (pH 7.6), 3 mM MnCl2, 3 mM MgCl2, 1 mM DTT, 10 M maker (Georgetown University, Washington, USA), and the antibody was
Na3VO4, 3 g/ml poly(Glu,Tyr) 4:1 (Sigma; St. Louis, Mo., USA), 1 % DMSO, produced and purified by conventional methods. For the ELISA, black 96-
1.0 M ATP (c-Met, c-Kit, c-Fms), 8.0 M ATP (KDR, Flt-1, Flk, Tek, FGFR- well Packard Opti Plates HTRF-96 (Packard, Zu¨rich, Switzerland) were
1), 10.0 M ATP (PDGFR-) (-[33P]-ATP 0.1 Ci), and were carried out for coated overnight with 50 l/well 0.1 g/ml mAB 24-60 in PBS and blocked
10–30 min at RT. with 3% BSA in PBST (PBS containing 0.05% Tween20). 40 l of each cell
Flt-3 lysate was transferred to the precoated plates, mixed with 40 l of an alkaline
Recombinant baculovirus that expresses the amino acid region 563–993 of phosphatase (AP) labeled anti-phosphotyrosine Ab (PY20[AP], Zymed; Ba-
the cytoplasmic kinase domains of human Flt-3 was generated. The coding sel, Switzerland), diluted to 0.2 g/ml in RIPA buffer, and incubated overnight
sequences for the cytoplasmic domain of Flt-3 were amplified by PCR from at 4C. After washing (PBST) and incubation for 45 min at RT with the
human c-DNA libraries (Clontech; Palo Alto CA, USA). Tyrosine protein kinase luminescent AP-substrate CDPStar RTU with Emerald II (90l/well), lumines-
assays with purified GST-Flt-3 was carried out for 15 min at RT in a final cence was measured using a Packard Top Count Scintillation Counter.
volume of 30 l containing 200–1800 ng of enzyme protein (depending on InsR
the specific activity), 20 mM Tris•HCl (pH 7.6), 3 mM MnCl2, 3 mM MgCl2, A commercial monoclonal anti-Ins-R--subunit antibody (Neomarkers Ab6,
1 mM DTT, 10 M Na3VO4, 3 g/mL poly(Glu,Tyr) 4:1 (Sigma; St. Louis, Basel, Switzerland) was used as a capture antibody for the insulin receptor.
Mo., USA), 1 % DMSO, 8.0 M ATP (-[33P]-ATP 0.1 Ci). Black ELISA plates were coated overnight with 50 l 0.75 g/ml Ab6 in PBS
Flt-4 at 4C, washed with PBST and blocked with PBST containing 3% BSA.
A fusion protein of GST and the cytoplasmic domain of human Flt-4 (GST- 5  103 A14 cells/well were plated on 96-well plates (Costar; Wohlen,
Flt-4) expressing the amino acid regions 725–1298 was provided by Dr. Switzerland) in complete growth medium and incubated at 37C, 5% CO2
Marme´ (Klinik fu¨r Tumour Biologie, Freiburg, Germany). GST-Flt-4 was as- until they reached confluency. After starvation for 24 hr in DMEM without
sayed for 15 min at RT in a final volume of 30 l containing 200–1800 ng FCS, followed by incubation for 90 min in the absence or presence of test
of enzyme protein (depending on the specific activity), 20 mM Tris•HCl (pH compound, the cells were stimulated with 5 g/ml insulin for 10 min at 37C.
7.6), 3 mM MnCl2, 3 mM MgCl2, 1 mM DTT, 10 M Na3VO4, 3 g/ml poly(Glu, Immediately after stimulation, the cells were washed twice with cold PBS,
Tyr) 4:1 (Sigma; St. Louis, MO, USA), 1% DMSO, 8.0 M ATP (-[33P]-ATP and lysed at 4C with 150 l/well freshly prepared RIPA buffer. 50 l of each
0.1 Ci). cell lysate was transferred directly from the cell culture plate to the precoated
plate and incubated overnight at 4C. Following washing with PBST, the
plates were incubated for 2 hr at RT with 50 l/well PY20(AP), diluted 1:10000Cell lines
NWT-21 cells are NIH3T3 mouse fibroblasts that stably overexpress the in RIPA buffer (final concentration: 0.1 g/ml). The final washing with PBST
was followed by addition of 90 l/well chemiluminescent AP-substratehuman IGF-IR and were generated as previously described (Kato et al.,
1993) by Dr. Thomas Geiger (Novartis Pharma AG). The cells were passaged (CDPStar RTU with Emerald II) and incubation for 45 min at RT (dark).
Luminescence was measured (as counts per second, CPS) with a Packardin DMEM high glucose, 10% FBS, and 1% Na-Pyruvate. A14 cells are
NIH3T3 mouse fibroblast cells that have been stably transfected with human TopCount Microplate Scintillation Counter.
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HER-1 Cruz; Nunningen, Switzerland) overnight at 4C on a rotating wheel. 30 l
Protein G Sepharose (Sigma; St. Louis, Mo., USA) were then added andA431 cells grown close to confluency in 96 well tissue culture plates were
starved for 24 hr in medium with 0.5% FBS, followed by incubation with incubation continued for 2 hr at 4C. The Protein G Sepharose was collected,
washed three times with lysis buffer, and resuspended in SDS-gel sampleserial dilutions of the compound for 90 min. After stimulation with a final
concentration of 50 ng/ml EGF (Upstate Biotechnology; 01-102, Frankfurt, buffer. Samples were loaded on 7.5% SDS gels (PAGErR Gold precast gels,
Bioconcept; Allschwil, Switzerland) and Western Blot was performed usingGermany) for 10 min, cells were washed and lysed in 150 l lysis buffer.
For the ELISA, 50 ng/well anti-EGFR Ab5 from NeoMarkers (MS-316-P; anti-phospho-Tyrosine antibody (4G10) followed by a secondary HRP-linked
anti-mouse Ig antibody (NA931V, Pharmacia, Du¨bendorf, Switzerland). Mem-Basel, Switzerland) was coated to black ELISA plates.
PDGFR branes were reprobed with anti-IGF-IR antibody (sc-713; Santa Cruz; Nun-
ningen, Switzerland). Alternatively, IGF-IR tyrosine phosphorylation was de-A31 cells grown in 96-well tissue culture plates close to confluency were
starved for 4 hr in the presence of 0.5% FCS, followed by incubation with termined on 50 g of total cell lysates obtained from NWT-21 cells cultured
in vitro using an anti-phospho-IGF-IR antibody (407707; Calbiochem/Merck;compound in starving medium for 2 hr. Subsequently, the cells were stimu-
lated with recombinant human PDGF BB (BACHEM, Bubendorf, Switzerland) Darmstadt, Germany), followed by a secondary HRP-coupled anti rabbit IgG
antibody (NA934V; Pharmacia; Du¨bendorf, Switzerland).at 50 ng/ml final concentration for 10 min followed by washing and lysis in
70 l/well lysis buffer. For the ELISA, 50 ng/well anti-PDGF-R Receptor Type PKB phosphorylation was determined using 20 g of the total cell
extract, resolved on 12% SDS gels (PAGErR Gold precast gels, Bioconcept;A/B antibody from Upstate Biotechnology (06-495; Frankfurt, Germany) was
coated to black ELISA plate. Allschwil, Switzerland). Western blot was performed using an anti-Phospho-
PKB (Ser473) antibody (9271, Cell Signaling; Frankfurt, Germany) or an anti-c-Kit
96-well tissue culture plates were treated with 1.5% gelatin solution in nano- PKB antibody (9272, Cell Signaling; Frankfurt, Germany), followed by a
secondary HRP-linked anti-mouse Ig antibody (NA931V, Pharmacia; Du¨ben-pure water for 30–60 min at 37C prior to seeding the GIST882 cells to
improve adherence and cell growth. The gelatin (EIA purity reagent; BIORAD, dorf, Switzerland).
MAPK kinase phosphorylation was determined using an antibody spe-Reinach, Switzerland) was sterilized before use by heating (autoclave). Cells
were grown close to confluency in gelatin-precoated 96-well tissue culture cific for phosphorylated threonine 202/tyrosine 204 of p44/42 MAPK (4102,
Cell Signaling; Frankfurt, Germany). The level of MAPK was monitored withplates. Incubation with compound for 90 min was followed by washing and
cell lysis in 100 l/well cold lysis buffer. For the ELISA, 100 ng per well a specific antibody (4101, Cell Signaling; Frankfurt, Germany).
Detection was performed using the ECL Plus western blotting detectionmonoclonal anti-CD117 antibody (Diaclone; Besanc¸on, France) was coated
to black ELISA plates. system (Amersham biosciences; Du¨bendorf, Switzerland).
Bcr-Abl
200,000 32D-Bcr-Abl cells were seeded per well in 96-well round bottom Proliferation assay
tissue culture plates and treated with compound for 90 min followed by Between 3000 and 6000 cells/well were seeded in 96-well plates with a total
washing and cell lysis in 150 l/well lysis buffer. For the ELISA, 50 ng/well media volume of 100 l/well. Increasing concentrations of the compound
of the rabbit polyclonal anti-abl-SH3 domain (Ab 06-466; Upstate; Frankfurt, were added 24 hr thereafter in quadruplicate. 72 hr later, cells were fixed
Germany) was coated to black ELISA plates. by addition of 25 l/well Glutaraldehyde (20%) and incubation for 10 min
at RT. Cells were then washed 2with 200 l/well H2O and 100 l Methylene
Blue (0.05%) was added. After incubation for 10 min at RT, cells wereIGF-I survival assay
MCF-7 cells were plated in 96-well dishes at 3000 cells/well in MEM EBS, washed 3 with 200 l/well H2O. 200 l/well HCl (3%) was added, and
following incubation for 30 min at RT on a plate shaker, absorbance was10% FCS, 1% Glutamate, 1% Na Pyruvate, and 10 g/ml bovine insulin
(Invitrogen; Basel, Switzerland). 24 hr after plating, medium was removed measured at 650 nm.
and the cells were washed twice with PBS. 100 l of serum-free medium
containing IGF-1 (50 ng/ml) and 0.1% BSA was added in the presence of Ex vivo analysis
increasing concentrations of compound. 72 hr after treatment started, cellu- Stimulation with IGF-I was induced by i.v. injection of the growth factor (0.1
lar viability was assayed using the Cell Titer 96R Aqueous One Solution Cell mg/kg) 5 min prior to euthanasia. Organs and tumor specimens derived
Proliferation Assay (Promega; Wallisellen, Switzerland). from treated animals were immediately snap frozen upon removal from the
animal. Samples were pulverized in a liquid nitrogen-cooled mortar and an
aliquot of approximately 50 mg placed in a dry-ice-cooled Eppendorf tube.Soft agar assay
MCF-7 cells were grown, as described above, and the soft agar assay was A 10 times equivalent volume of boiling extraction buffer was added (100
mM Tris·HCl [pH 7.4], 2% SDS, 10 mM DTT, 2 mM Sodium Vanadate, 0.5adapted to 24-well plates according to the method described previously
(Freedman and Shin, 1974). NVP-AEW541 was added directly to the agar- mM EDTA, 0.1 mM PMSF). Following extensive vortexing, the sample was
boiled for 10 min at 95C with occasional vigorous vortexing. Followingcontaining medium, to final concentrations of 30 to 300 nM. The basal layer
contained 0.5 ml per well of 0.8% bacto agar (Invitrogen; Basel, Switzerland) preclearing by centrifugation at 4C and 14,000 rpm for 15 min, the superna-
tant was transferred to a precooled Eppendorf and the protein concentrationin MCF7 growth medium. The plates were covered and stored in an incubator
(37C, 5% CO2) for at least 30 min to allow the medium to solidify before assayed. Immunoprecipitation and Western blot analysis were carried out
as described above.addition of the top agar layer. 5000 MCF-7 cells per well were embedded
in 0.5 ml top layer of 0.4% agar in growth medium. After 3 weeks incubation
at 37C, 5% CO2, cells were fixed, stained by crystal violet, positive colonies In vivo efficacy study
(diameter  40 m) counted, and the transformation efficiency determined All experimental procedures strictly adhered to the Eidgeno¨ssisches
using a Kontron KS-400 image analysis system (Zeiss; Jena, Germany). Tierschutzgesetz and the Eidgeno¨ssische Tierschutzverordnung and were
covered by the permit No. 1763 issued by the Kantonale Veterina¨ramt Basel-
Stadt (Switzerland). Female Harlan athymic nude mice were obtained fromWestern blot analysis of phospho-IGF-IR, phospho-PKB,
and phospho-MAPK a Novartis internal breeding population (Hsd:Athymic Nude-nu) and were
kept under optimal hygienic conditions. The initial body weight of the animalsIGF-IR phosphorylation was tested in log phase cells. The compound (dis-
solved in DMSO) was added 20 min before stimulation with IGF-I (50 ng/ml) at time of arrival was between 18 and 25 g. The animals were kept in
Makrolon type III cages (8 animals per cage) in a 12 hr/12 hr light/dark cycle,to reach final concentrations ranging from 0.1 to 10 M. Ten minutes thereaf-
ter, the dishes were placed on ice, cells rinsed with 10 ml cold PBS, and and food and water were ad libitum. At the end of the experiment, animals
were sacrificed by CO2 inhalation.collected in 500 l lysis buffer (50 mM Tris·HCl [pH 7.5], 120 mM NaCl, 20
mM NaF, 1 mM EDTA, 6 mM EGTA, 15 mM pNPP, 15 mM Sodiumpyrophos- Generation of NWT-21 tumor fragments and treatment of animals was
performed as follows. NWT-21 cells were grown in DMEM (high glucose,phate, 1 mM Benzamidin, 0.1 mM PMSF, 0.5 mM Vanadate, 1% NP-40).
Protein concentration was determined using Coomasie R Plus Protein Assay 4.5 g/l), 10% FCS, 1% L-glutamine, and 1% Na-pyruvate. 5  106 cells/
animal were initially injected s.c. into the right flank of five mice. For theReagent Kit (Pierce; Lausanne, Switzerland). Between 800 g and 1 mg of
total cell lysate were incubated with 2 g specific anti-IGF-IR (C-20; Santa in vivo efficacy experiment, tumors of 500 to 800 mm3 were excised and
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growth and prevents invasion by rat prostate cancer cells in vivo. Proc. Natl.nonnecrotic areas were cut to fragments of 3 3  3 mm. Tumor fragments
Acad. Sci. USA 93, 7263–7268.were washed in sterile PBS and one tumor fragment per animal was trans-
planted s.c. into the right flank. Tumor volumes (length  width  height  Capraro, H.G., Furet, P., Garcia-Echeverria, C., and Manley, P.W. (2002).

 / 6) and body weights were determined three times weekly. At the first 4-amino-5-phenyl-7-cyclobutyl-pyrrolo[2,3-d]pyrimidine derivatives. PCT
day of treatment (day 0), the therapy group (NVP-AEW541) and the control International Patent Application Publication WO 02/92599.
group (vehicle only) were selected by stratification (8 animals per group,
Chernicky, C.L., Yi, L., Tan, H., Gan, S.U., and Ilan, J. (2000). Treatment ofaverage tumor volume of about 95 mm3 per group). Animals were treated
human breast cancer cells with antisense RNA to the type I insulin-likep.o. twice daily, 7 days/week either with NVP-AEW541 (20, 30, or 50 mg/kg;
growth factor receptor inhibits cell growth, suppresses tumourogenesis,10 ml/kg dissolved in 25 mM L(	)-tartaric acid, therapy group) or with 25
alters the metastatic potential and prolongs survival in vivo. Cancer GenemM L(	)-tartaric acid (control group). Antitumor activity was expressed as
Ther. 7, 384–395.T/C% (mean increase of tumor volumes of treated animals divided by the mean
increase of tumor volumes of control animals multiplied by 100). The experiment Coppola, D., Ferber, A., Miura, M., Sell, C., D’Ambrosio, C., Rubin, R., and
was terminated when the mean tumor volume was about 1500 mm3. Baserga, R. (1994). A functional insulin-like growth factor I receptor is re-
Results are presented as mean  standard error of the mean (SEM). quired for the mitogenic and transforming activities of the epidermal growth
The differences in tumor volumes and body weights were statistically ana- factor receptor. Mol. Cell. Biol. 14, 4588–4595.
lyzed using one-way ANOVA with Dunnett test. The level of significance was
D’Ambrosio, C., Ferber, A., Resnicoff, N., and Baserga, R. (1996). A solubleset at p  0.05. Statistical analyses were performed using SigmaStat 2.03
Insulin-like growth factor I receptor that induces apoptosis of tumour cells(Jandel Scientific; Zu¨rich, Switzerland).
in vivo and inhibits tumourogenesis. Cancer Res. 56, 4013–4020.
Compound synthesis De Angelis, T., Ferber, A., and Baserga, R. (1995). R. Insulin-like growth
factor I receptor is required for the mitogenic and transforming activities ofNVP-AEW541 is a pyrrolo[2,3-d]pyrimidine derivative synthesized at Novartis
the platelet-derived growth factor receptor. J. Cell. Physiol. 164, 214–221.Pharma AG, Basel, Switzerland (Capraro et al., 2002).
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